Perfluorohexyloctane is a drug used to treat dry eye disease. Perfluorohexyloctane is a semifluorinated alkane that contains six perfluorinated carbon atoms and eight hydrogenated carbon atoms.
- Mechanism
- Curator reviewed · 4 references
Perfluorohexyloctane mediates its actions in the lipid layer and meibomian glands. While the exact mechanism of action is not fully understood, perfluorohexyloctane is believed to interact with the air-liquid interface of the tear film and form a monolayer, preventing the evaporation of the aqueous phase of the tears.
- Primary indication
- Perfluorohexyloctane ophthalmic formulation is indicated for the treatment of the signs and symptoms of dry eye disease.Curator reviewed · 1 structured indication
- Formula / weight
- C14H17F13 · 432.269 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2023
- Also known as
- 1-(perfluorohexyl)octane · F6H8 · NOV03 · Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-
- Brand names
Resolves to
WRYIIOKOQSICTB-UHFFFAOYSA-NSMILESCCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)FWhat you can answer from here — as of July 24, 2025
Which other approved drugs treat the same conditions as Perfluorohexyloctane, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account